Brokerages Set Enfusion, Inc. (NYSE:ENFN) Price Target at $10.25

Shares of Enfusion, Inc. (NYSE:ENFN) have received a consensus rating of “Reduce” from the seven brokerages that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $10.25.

Several research firms have recently issued reports on ENFN. William Blair reiterated a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Stifel Nicolaus lifted their price target on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Finally, Piper Sandler increased their price objective on shares of Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd.

Enfusion Trading Up 0.9 %

NYSE:ENFN opened at $11.06 on Friday. The stock has a 50-day moving average price of $10.28 and a 200 day moving average price of $9.28. The stock has a market capitalization of $1.42 billion, a P/E ratio of 276.44, a P/E/G ratio of 1.58 and a beta of 0.95. Enfusion has a 12-month low of $7.52 and a 12-month high of $11.38.

Insider Activity

In related news, COO Neal Pawar sold 21,801 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the sale, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Bradley Herring sold 24,443 shares of Enfusion stock in a transaction on Friday, December 20th. The stock was sold at an average price of $10.61, for a total transaction of $259,340.23. Following the transaction, the chief financial officer now directly owns 270,503 shares of the company’s stock, valued at $2,870,036.83. The trade was a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 58,041 shares of company stock worth $597,367. 36.44% of the stock is currently owned by corporate insiders.

Institutional Trading of Enfusion

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENFN. TenCore Partners LP purchased a new position in shares of Enfusion during the third quarter valued at approximately $3,938,000. Dimensional Fund Advisors LP boosted its holdings in Enfusion by 57.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock valued at $4,466,000 after acquiring an additional 191,436 shares during the period. JPMorgan Chase & Co. grew its position in Enfusion by 612.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock valued at $1,974,000 after acquiring an additional 178,821 shares during the last quarter. Impax Asset Management Group plc increased its stake in Enfusion by 25.4% in the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock worth $6,424,000 after purchasing an additional 136,948 shares during the period. Finally, Scalar Gauge Management LLC lifted its position in shares of Enfusion by 21.8% during the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after purchasing an additional 110,000 shares during the last quarter. 81.05% of the stock is owned by hedge funds and other institutional investors.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.